Myeloid to Adipocyte Transdifferentiation in Human Cells

NCT ID: NCT02654925

Last Updated: 2021-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

59 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2021-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to design new programs to help prevent weight gain, promote successful and sustainable weight loss, and help treat diseases related to obesity, the investigators need a better understanding of why accumulating fat in certain regions of the body is bad for health. It is known that not all fat cells are the same, but it was recently discovered that some fat cells may arise from stem cells that come from the bone marrow (bone marrow progenitors), a previously unrecognized origin. This discovery has been paradigm shifting, because dogma has long held that all white fat cells arise from fat tissue resident mesenchymal stem cells. This is also important because fat cells arising from the bone marrow lineage may be linked to worse health outcomes. The aim of this study is to determine if cells that were not previously believed to contribute to fat generation in humans are indeed capable of becoming fat cells. To answer this question the investigators will take samples of cells from the blood and the fat tissue of younger and older men and women, isolate the cells that came from the bone marrow and grow them in culture to determine if they will turn into fat cells. The results of this investigation may reveal potential mechanistic targets for future therapies to reduce the negative health outcomes associated with obesity related chronic diseases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young Men

men 21-40 years of age

Adipose Tissue Biopsy

Intervention Type PROCEDURE

Young Women

women 21-40 years of age; young women will be premenopausal and eumenorrheic, not on hormonal contraceptive therapy.

Adipose Tissue Biopsy

Intervention Type PROCEDURE

Older Men

men 55-100 years of age

Adipose Tissue Biopsy

Intervention Type PROCEDURE

Older Women

women 55-100 years of age; older women will be postmenopausal who are at least 12 months past the final menstrual period (FMP).

Adipose Tissue Biopsy

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adipose Tissue Biopsy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women age 21-40 y or 55-100 y;
* Older women will be postmenopausal who are at least 12 months past the final menstrual period (FMP);
* Young women will be premenopausal and eumenorrheic, not on hormonal contraceptive therapy;
* Body Mass Index (BMI) 22-35 kg/m2;
* Non-active to moderately active (vigorous exercise ≤ 3 days/wk lasting \< 30 min).

Exclusion Criteria

* Immunosuppression therapy;
* On blood thinners, aspirin, or NSAIDs that cannot be withheld for the biopsy;
* Prior history of allergies to local anesthetics;
* Current use of hormones, or glucose lowering medication;
* Currently engaged in a vigorous exercise or diet program;
* Currently gaining or losing weight or using weight loss drugs;
* Type 2 diabetes (past/current diagnosis or treatment);
* Diagnosis of uncontrolled metabolic disorders (e.g., thyroid);
* History of severe obesity BMI ≥ 40 or significant weight loss (≥ 50 lbs);
* Postmenopausal - hormonal menopausal therapy use currently or in the previous 6 months;
* Premenopausal - irregular menstrual cycles defined as 2 or more missed cycles in the previous year, pregnant or planning to become pregnant during the study timeline (urine pregnancy test will be performed before DEXA \[dual energy x-ray absorptiometry\] scan is completed).
Minimum Eligible Age

21 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Colorado, Denver

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kathleen M Gavin, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado Denver Anschutz Medical Campus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UL1TR001082

Identifier Type: NIH

Identifier Source: secondary_id

View Link

15-1779

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.